Tempus xT Cancer Genome Sequencing Panel

Tempus has introduced Tempus xT, a genome sequencing panel that analyzes 595 genes related to diagnosis, prognosis, and therapeutic targeting of cancer. Among other things, the panel looks for single-nucleotide variants, small insertions and deletions, amplifications of copy numbers, and structural alterations that could cause fusions, the company said. Chicago-based Tempus will run the xT panel at its own next-generation sequencing lab.